참고문헌
- El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-1127 https://doi.org/10.1056/NEJMra1001683
- Global Burden of Disease Liver Cancer Collaboration; Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol 2017;3:1683-1691 https://doi.org/10.1001/jamaoncol.2017.3055
- Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022 https://doi.org/10.1002/hep.24199
- Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67:358-380 https://doi.org/10.1002/hep.29086
- Cescon M, Cucchetti A, Ravaioli M, Pinna AD. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. J Hepatol 2013;58:609-618 https://doi.org/10.1016/j.jhep.2012.09.021
- Ho MH, Yu CY, Chung KP, Chen TW, Chu HC, Lin CK, et al. Locoregional therapy-induced tumor necrosis as a predictor of recurrence after liver transplant in patients with hepatocellular carcinoma. Ann Surg Oncol 2011;18:3632-3639 https://doi.org/10.1245/s10434-011-1803-3
- Allard MA, Sebagh M, Ruiz A, Guettier C, Paule B, Vibert E, et al. Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation? J Hepatol 2015;63:83-92 https://doi.org/10.1016/j.jhep.2015.01.023
- American College of Radiology. CT/MRI LI-RADS® v2017. Acr.org Web site. https://www.acr.org/Clinical-Resources/ Reporting-and-Data-Systems/LI-RADS/CT-MRI-LI-RADS-v2017. Accessed November 3, 2020
- Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60 https://doi.org/10.1055/s-0030-1247132
- Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430 https://doi.org/10.1016/S0168-8278(01)00130-1
- Kielar A, Fowler KJ, Lewis S, Yaghmai V, Miller FH, Yarmohammadi H, et al. Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm. Abdom Radiol (NY) 2018;43:218-230 https://doi.org/10.1007/s00261-017-1281-6
- Shropshire EL, Chaudhry M, Miller CM, Allen BC, Bozdogan E, Cardona DM, et al. LI-RADS treatment response algorithm: performance and diagnostic accuracy. Radiology 2019;292:226-234 https://doi.org/10.1148/radiol.2019182135
- Kim SW, Joo I, Kim HC, Ahn SJ, Kang HJ, Jeon SK, et al. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features. Eur Radiol 2020;30:2861-2870 https://doi.org/10.1007/s00330-019-06623-9
- Seo N, Kim MS, Park MS, Choi JY, Do RKG, Han K, et al. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017. Eur Radiol 2020;30:261-271 https://doi.org/10.1007/s00330-019-06376-5
- Chaudhry M, McGinty KA, Mervak B, Lerebours R, Li C, Shropshire E, et al. The LI-RADS version 2018 MRI treatment response algorithm: evaluation of ablated hepatocellular carcinoma. Radiology 2020;294:320-326 https://doi.org/10.1148/radiol.2019191581
- Yu JS, Kim YH, Rofsky NM. Dynamic subtraction magnetic resonance imaging of cirrhotic liver: assessment of high signal intensity lesions on nonenhanced T1-weighted images. J Comput Assist Tomogr 2005;29:51-58 https://doi.org/10.1097/01.rct.0000152846.06095.b3
- Tirkes T, Mehta P, Aisen AM, Lall C, Akisik F. Comparison of dynamic phase enhancement of hepatocellular carcinoma using gadoxetate disodium vs gadobenate dimeglumine. J Comput Assist Tomogr 2015;39:479-482 https://doi.org/10.1097/RCT.0000000000000234
- Kim S, Mannelli L, Hajdu CH, Babb JS, Clark TW, Hecht EM, et al. Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction. J Magn Reson Imaging 2010;31:348-355 https://doi.org/10.1002/jmri.22038
- Gordic S, Corcuera-Solano I, Stueck A, Besa C, Argiriadi P, Guniganti P, et al. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology. J Hepatol 2017;67:1213-1221 https://doi.org/10.1016/j.jhep.2017.07.030
- Kim DH, Choi SH, Byun JH, Kang JH, Lim YS, Lee SJ, et al. Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma. J Hepatol 2019;71:534-542 https://doi.org/10.1016/j.jhep.2019.05.005
- Sundarakumar DK, Wilson GJ, Osman SF, Zaidi SF, Maki JH. Evaluation of image registration in subtracted 3D dynamic contrast-enhanced MRI of treated hepatocellular carcinoma. AJR Am J Roentgenol 2015;204:287-296 https://doi.org/10.2214/AJR.13.12417
- American College of Radiology. CT/MRI LI-RADS® v2018. Acr.org Web site. https://www.acr.org/Clinical-Resources/ Reporting-and-Data-Systems/LI-RADS/CT-MRI-LI-RADS-v2018. Accessed November 3, 2020
- Cools KS, Moon AM, Burke LMB, McGinty KA, Strassle PD, Gerber DA. Validation of the liver imaging reporting and data system treatment response criteria after thermal ablation for hepatocellular carcinoma. Liver Transpl 2020;26:203-214 https://doi.org/10.1002/lt.25673
- Mannelli L, Kim S, Hajdu CH, Babb JS, Clark TW, Taouli B. Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol 2009;193:1044-1052 https://doi.org/10.2214/AJR.08.1461
- Choi SH, Kim SY, Lee SS, Shim JH, Byun JH, Baek S, et al. Subtraction images of gadoxetic acid-enhanced MRI: effect on the diagnostic performance for focal hepatic lesions in patients at risk for hepatocellular carcinoma. AJR Am J Roentgenol 2017;209:584-591 https://doi.org/10.2214/AJR.16.17211